Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2006, Article ID 68091, 9 pages
http://dx.doi.org/10.1155/JBB/2006/68091
Methods Report

Cloning and Expression of Human Membrane-Bound and Soluble Engineered T Cell Receptors for Immunotherapy

Department of Immunology, School of Medicine, University of Pittsburgh, PA, Pittsburgh 15261, USA

Received 28 June 2005; Revised 15 November 2005; Accepted 21 November 2005

Copyright © 2006 Nehad M. Alajez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M E Dudley, J R Wunderlich, P F Robbins et al., “Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes,” Science, vol. 298, no. 5594, pp. 850–854, 2002. View at Publisher · View at Google Scholar
  2. M P Rubinstein, A N Kadima, M L Salem et al., “Transfer of TCR genes into mature T cells is accompanied by the maintenance of parental T cell avidity,” The Journal of Immunology, vol. 170, no. 3, pp. 1209–1217, 2003. View at Google Scholar
  3. R A Morgan, M E Dudley, Y Y Yu et al., “High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens,” The Journal of Immunology, vol. 171, no. 6, pp. 3287–3295, 2003. View at Google Scholar
  4. C A Aarnoudse, M Krüse, R Konopitzky, N Brouwenstijn, and P I Schrier, “TCR reconstitution in Jurkat reporter cells facilitates the identification of novel tumor antigens by cDNA expression cloning,” International Journal of Cancer, vol. 99, no. 1, pp. 7–13, 2002. View at Publisher · View at Google Scholar
  5. M A Derby, J Wang, D H Margulies, and J A Berzofsky, “Two intermediate-avidity cytotoxic T lymphocyte clones with a disparity between functional avidity and MHC tetramer staining,” International Immunology, vol. 13, no. 6, pp. 817–824, 2001. View at Publisher · View at Google Scholar
  6. J T Snyder, M A Alexander-Miller, J A Berzofsky, and I M Belyakov, “Molecular mechanisms and biological significance of CTL avidity,” Current HIV Research, vol. 1, no. 3, pp. 287–294, 2003. View at Publisher · View at Google Scholar
  7. M E Weijtens, E H Hart, and R L Bolhuis, “Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production,” Gene Therapy, vol. 7, no. 1, pp. 35–42, 2000. View at Publisher · View at Google Scholar
  8. S Yang, G P Linette, S Longerich, and F G Haluska, “Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity,” The Journal of Immunology, vol. 169, no. 1, pp. 531–539, 2002. View at Google Scholar
  9. J Magarian-Blander, P Ciborowski, S Hsia, S C Watkins, and O J Finn, “Intercellular and intracellular events following the MHC-unrestricted TCR recognition of a tumor-specific peptide epitope on the epithelial antigen MUC1,” The Journal of Immunology, vol. 160, no. 7, pp. 3111–3120, 1998. View at Google Scholar
  10. I Engel, T H Ottenhoff, and R D Klausner, “High-efficiency expression and solubilization of functional T cell antigen receptor heterodimers,” Science, vol. 256, no. 5061, pp. 1318–1321, 1992. View at Publisher · View at Google Scholar
  11. M Mittelbrunn, M Yáñez-Mó, D Sancho, A Ursa, and F Sánchez-Madrid, “Cutting edge: dynamic redistribution of tetraspanin CD81 at the central zone of the immune synapse in both T lymphocytes and APC,” The Journal of Immunology, vol. 169, no. 12, pp. 6691–6695, 2002. View at Google Scholar
  12. N M Alajez, J Schmielau, M D Alter, M Cascio, and O J Finn, “Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution,” Blood, vol. 105, no. 12, pp. 4583–4589, 2005. View at Publisher · View at Google Scholar
  13. R A Willemsen, M E Weijtens, C Ronteltap et al., “Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR,” Gene Therapy, vol. 7, no. 16, pp. 1369–1377, 2000. View at Publisher · View at Google Scholar
  14. J Novotny, R K Ganju, S T Smiley et al., “A soluble, single-chain T-cell receptor fragment endowed with antigen-combining properties,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 19, pp. 8646–8650, 1991. View at Publisher · View at Google Scholar
  15. Z Eshhar, N Bach, C J Fitzer-Attas et al., “The T-body approach: potential for cancer immunotherapy,” Springer Seminars in Immunopathology, vol. 18, no. 2, pp. 199–209, 1996. View at Publisher · View at Google Scholar
  16. C Grégoire, S Y Lin, G Mazza, N Rebai, I F Luescher, and B Malissen, “Covalent assembly of a soluble T cell receptor-peptide-major histocompatibility class I complex,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 14, pp. 7184–7189, 1996. View at Google Scholar
  17. G Pavlinkova, D Colcher, B J Booth, A Goel, and S K Batra, “Pharmacokinetics and biodistribution of a light-chain-shuffled CC49 single-chain Fv antibody construct,” Cancer Immunology, Immunotherapy, vol. 49, no. 4-5, pp. 267–275, 2000. View at Publisher · View at Google Scholar